Exact Mass: 534.2577
Exact Mass Matches: 534.2577
Found 500 metabolites which its exact mass value is equals to given mass value 534.2577
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
GV 150013X
Pyropheophorbide a
Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT)[1].
3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside]
3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside] is found in fruits. 3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside] is a constituent of Cydonia oblonga (quince). Constituent of Cydonia oblonga (quince). 3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside] is found in fruits.
7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside]
7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside] is found in fruits. 7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside] is a constituent of leaves of quince (Cydonia vulgaris)
Pyrophaeophorbide a
Pyrophaeophorbide a is found in tea. Pyrophaeophorbide a is isolated from te Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT)[1].
8-{2-Methyl-5-[2-oxo-2-(4-phenyl-piperazin-1-yl)-ethoxy]-2H-pyrazol-3-yl}-1,3-dipropyl-3,7-dihydro-purine-2,6-dione
Daglutril
Phytoporphyrin
Pyropheophorbide a
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
N,N-bis[2-[(2-chlorobenzyl)-diethyl-ammonio]ethyl]oxalimidate
2beta,9-dihydroxymegastigma-4-en-3-one 9-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside
3beta,6alpha-dihydroxy-1alpha,7beta,11beta,15beta-tetraacetoxy-6,18-cyclo-ent-kaur-16-ene|nervonin A
4-N-Ac,4,6-O-Benzylidene-beta-D-4-Aminophenyl 2-acetamido-2-deoxyglucopyranoside
(3E,7E)-2alpha,10beta,13alpha,20-tetraacetoxy-5alpha-hydroxy-3,8-secotaxa-3,7,11-trien-9-one
(22SR,23SR,24RS,25SR)-12alpha,22:21,24-diepoxy-5alpha,6beta,12beta,17beta,25-pentahydroxy-1-oxo-with-2-en-26,23-olide|jaborosalactone 35
asterriquinone dimethyl ether
A member of the class of asterriquinones that is asterriquinone in which the hydrogens of both of the hydroxy groups have replaced by methyl groups.
2alpha,5alpha,7beta,13alpha-tetraacetoxy-10beta-hydroxyl-2(3->20)abeotaxan-9-one|2??,5??,7??,13??-Tetraacetoxy-10??-hydroxy-2(3鈥樏傗垎20)abeotaxan-9-one
(13-hydroxyblumenol C) 9-O-beta-(6-O-rhamnosylglucoside)
(1R*,2R*,3S*,5Z,7S*,8S*,9S*,10S*,11Z,14S*,17R*)-2,14-diacetoxy-3-butyrloxy-8,17-epoxy-9-hydroxybriara-5,11-dien-18-one
(4beta,5beta,6alpha,18R,22R)-6-chloro-18,20-epoxy-4,5,22-trihydroxy-18-methoxy-1-oxoergost-2,24-dien-26-oic acid gamma-lactone|withaphysalin V
(3E,7E)-2alpha,5alpha,10beta,13alpha-tetraacetoxy-20-hydroxy-3,8-secotaxa-3,7,11-trien-9-one
(2E)-1-{2,4-dihydroxy-3-[(1R,2E,5S)-5-hydroxy-1,7-diphenylhept-2-en-1-yl]-6-methoxyphenyl}-3-phenylprop-2-en-1-one|katsumain B
12alpha-Brom-3beta,13-dihydroxy-oleanan-28-saeure-13-lacton|12alpha-bromo-3beta,13-dihydroxy-oleanan-28-oic acid-13-lactone|12alpha-bromo-3beta,13beta-dihydroxyolean-28-oic acid gamma-lactone|12alpha-bromo-3beta-hydroxy-oleanan-13beta,28-olide
Bulleyanin
2??-Acetoxy-4??-hydroxy-6??-p-hydroxybenzoyloxy-10??-benzoyloxy-dauc-8-ene
C28H38O10_Methyl 5-acetoxy-6,10-dihydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylene-1,4,8-trioxohexadecahydro-2H-naphtho[1,2-h]isochromene-2-carboxylate
C28H38O10_1H-Pyrano[3,4:5,6]naphth[2,1-c]oxepin-3,8,11(9H)-trione, 5,12-bis(acetyloxy)dodecahydro-13-hydroxy-1,1,5a,7a,9,11b-hexamethyl-7-methylene
SB236057A
CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8057; ORIGINAL_PRECURSOR_SCAN_NO 8055 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8094; ORIGINAL_PRECURSOR_SCAN_NO 8093 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8100; ORIGINAL_PRECURSOR_SCAN_NO 8098 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8129; ORIGINAL_PRECURSOR_SCAN_NO 8126 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8145; ORIGINAL_PRECURSOR_SCAN_NO 8143 CONFIDENCE standard compound; INTERNAL_ID 629; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8145; ORIGINAL_PRECURSOR_SCAN_NO 8144
Ala Cys Arg Trp
Ala Cys Trp Arg
Ala Lys Met Trp
Ala Lys Trp Met
Ala Met Lys Trp
Ala Met Trp Lys
Ala Arg Cys Trp
Ala Arg Trp Cys
Ala Trp Cys Arg
Ala Trp Lys Met
Ala Trp Met Lys
Ala Trp Arg Cys
Cys Ala Arg Trp
Cys Ala Trp Arg
Cys Glu Lys Arg
Cys Glu Arg Lys
Cys Lys Glu Arg
Cys Lys Arg Glu
Cys Lys Val Trp
Cys Lys Trp Val
Cys Arg Ala Trp
Cys Arg Glu Lys
Cys Arg Lys Glu
Cys Arg Arg Thr
Cys Arg Thr Arg
Cys Arg Trp Ala
Cys Thr Arg Arg
Cys Val Lys Trp
Cys Val Trp Lys
Cys Trp Ala Arg
Cys Trp Lys Val
Cys Trp Arg Ala
Cys Trp Val Lys
Asp Lys Ser Trp
Asp Lys Trp Ser
Asp Ser Lys Trp
Asp Ser Trp Lys
Asp Trp Lys Ser
Asp Trp Ser Lys
Glu Cys Lys Arg
Glu Cys Arg Lys
Glu His His Ile
Glu His His Leu
Glu His Ile His
Glu His Leu His
Glu Ile His His
Glu Lys Cys Arg
Glu Lys Met Gln
Glu Lys Gln Met
Glu Lys Arg Cys
Glu Leu His His
Glu Met Lys Gln
Glu Met Gln Lys
Glu Gln Lys Met
Glu Gln Met Lys
Glu Arg Cys Lys
Glu Arg Lys Cys
Phe Gln Leu Gln
His Glu His Ile
His Glu His Leu
His Glu Ile His
His Glu Leu His
His His Glu Ile
His His Glu Leu
His His Ile Glu
His His Lys Asn
His His Leu Glu
His His Asn Lys
His Ile Glu His
His Ile His Glu
His Lys His Asn
His Lys Asn His
His Leu Glu His
His Leu His Glu
His Asn His Lys
His Asn Lys His
Ile Glu His His
Ile His Glu His
Ile His His Glu
Lys Ala Met Trp
Lys Ala Trp Met
Lys Cys Glu Arg
Lys Cys Arg Glu
Lys Cys Val Trp
Lys Cys Trp Val
Lys Asp Ser Trp
Lys Asp Trp Ser
Lys Glu Cys Arg
Lys Glu Met Gln
Lys Glu Gln Met
Lys Glu Arg Cys
Lys His His Asn
Lys His Asn His
Lys Met Ala Trp
Lys Met Glu Gln
Lys Met Gln Glu
Lys Met Trp Ala
Lys Asn His His
Lys Gln Glu Met
Lys Gln Met Glu
Lys Arg Cys Glu
Lys Arg Glu Cys
Lys Ser Asp Trp
Lys Ser Trp Asp
Lys Val Cys Trp
Lys Val Trp Cys
Lys Trp Ala Met
Lys Trp Cys Val
Lys Trp Asp Ser
Lys Trp Met Ala
Lys Trp Ser Asp
Lys Trp Val Cys
Leu Glu His His
Leu His Glu His
Leu His His Glu
Met Ala Lys Trp
Met Ala Trp Lys
Met Glu Lys Gln
Met Glu Gln Lys
Met Lys Ala Trp
Met Lys Glu Gln
Met Lys Gln Glu
Met Lys Trp Ala
Met Gln Glu Lys
Met Gln Lys Glu
Met Gln Arg Thr
Met Gln Thr Arg
Met Arg Gln Thr
Met Arg Thr Gln
Met Thr Gln Arg
Met Thr Arg Gln
Met Trp Ala Lys
Met Trp Lys Ala
Asn His His Lys
Asn His Lys His
Asn Lys His His
Pro Gln Gln Tyr
Pro Gln Tyr Lys
Pro Gln Tyr Gln
Pro Tyr Lys Gln
Pro Tyr Gln Lys
Pro Tyr Gln Gln
Gln Glu Lys Met
Gln Glu Met Lys
Gln Phe Ile Gln
Gln Phe Leu Gln
Gln Phe Gln Ile
Gln Phe Gln Leu
Gln Ile Phe Gln
Gln Ile Gln Phe
Gln Lys Glu Met
Gln Lys Met Glu
Gln Met Glu Lys
Gln Met Lys Glu
Gln Met Arg Thr
Gln Met Thr Arg
Gln Pro Gln Tyr
Gln Pro Tyr Gln
Gln Gln Pro Tyr
Gln Gln Tyr Pro
Gln Arg Met Thr
Gln Arg Thr Met
Gln Thr Met Arg
Gln Thr Arg Met
Gln Thr Thr Trp
Gln Thr Trp Thr
Gln Trp Thr Thr
Gln Tyr Pro Gln
Gln Tyr Gln Pro
Arg Ala Cys Trp
Arg Ala Trp Cys
Arg Cys Ala Trp
Arg Cys Glu Lys
Arg Cys Lys Glu
Arg Cys Arg Thr
Arg Cys Thr Arg
Arg Cys Trp Ala
Arg Glu Cys Lys
Arg Glu Lys Cys
Arg Lys Cys Glu
Arg Lys Glu Cys
Arg Met Gln Thr
Arg Met Thr Gln
Arg Gln Met Thr
Arg Gln Thr Met
Arg Arg Cys Thr
Arg Arg Thr Cys
Arg Ser Ser Trp
Arg Ser Trp Ser
Arg Thr Cys Arg
Arg Thr Met Gln
Arg Thr Gln Met
Arg Thr Arg Cys
Arg Trp Ala Cys
Arg Trp Cys Ala
Arg Trp Ser Ser
Ser Asp Lys Trp
Ser Asp Trp Lys
Ser Lys Asp Trp
Ser Lys Trp Asp
Ser Arg Ser Trp
Ser Arg Trp Ser
Ser Ser Arg Trp
Ser Ser Trp Arg
Ser Trp Asp Lys
Ser Trp Lys Asp
Ser Trp Arg Ser
Ser Trp Ser Arg
Thr Cys Arg Arg
Thr Met Gln Arg
Thr Met Arg Gln
Thr Gln Met Arg
Thr Gln Arg Met
Thr Gln Thr Trp
Thr Gln Trp Thr
Thr Arg Cys Arg
Thr Arg Met Gln
Thr Arg Gln Met
Thr Arg Arg Cys
Thr Thr Gln Trp
Thr Thr Trp Gln
Thr Trp Gln Thr
Thr Trp Thr Gln
Val Cys Lys Trp
Val Cys Trp Lys
Val Lys Cys Trp
Val Lys Trp Cys
Val Trp Cys Lys
Val Trp Lys Cys
Trp Ala Cys Arg
Trp Ala Lys Met
Trp Ala Met Lys
Trp Ala Arg Cys
Trp Cys Ala Arg
Trp Cys Lys Val
Trp Cys Arg Ala
Trp Cys Val Lys
Trp Asp Lys Ser
Trp Asp Ser Lys
Trp Lys Ala Met
Trp Lys Cys Val
Trp Lys Asp Ser
Trp Lys Met Ala
Trp Lys Ser Asp
Trp Lys Val Cys
Trp Met Ala Lys
Trp Met Lys Ala
Trp Gln Thr Thr
Trp Arg Ala Cys
Trp Arg Cys Ala
Trp Arg Ser Ser
Trp Ser Asp Lys
Trp Ser Lys Asp
Trp Ser Arg Ser
Trp Ser Ser Arg
Trp Thr Gln Thr
Trp Thr Thr Gln
Trp Val Cys Lys
Trp Val Lys Cys
Tyr Pro Gln Gln
Tyr Gln Pro Gln
Tyr Gln Gln Pro
7,8-Dihydrovomifoliol 9-[rhamnosyl-(1->6)-glucoside]
9-[2-(Butoxycarbonyl)phenyl]-6-(diethylamino)-N,N-diethyl-3H-xant hen-3-iminium chloride
(1R,2R)-N,N-Dihydroxy-N,N-bis(diphenylacetyl)cyclohexane-1,2-diamine
Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate
(1S,2S)-N,N-Dihydroxy-N,N-bis(diphenylacetyl)cyclohexane-1,2-diamine
Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
1H-1-Benzazepine-1-acetic acid, 3-[[[1-[2-(ethoxycarbonyl)-4-phenylbutyl]cyclopentyl]carbonyl]amino]-2,3,4,5-tetrahydro-2-oxo-
1-[(3R)-1-(1-adamantylmethyl)-2,4-dioxo-5-phenyl-1,5-benzodiazepin-3-yl]-3-phenylurea
(1-Ethyl-6,7-dihydro-5H-spiro(furo(2,3-f)indole-3,4-piperidin)-5-yl)(2-methyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-yl)methanone
3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid
longirostrerone D
A natural product found in Chaetomium longirostre. An azaphilone that is 6H-furo[2,3-h]isochromene-6,8(6aH)-dione substituted by a 4-hydroxy-2-methyl-6-oxocyclohexyl group at position 3, a methyl group at position 6a, and a 4,6,8-trimethyldeca-2,4-dienoyl group at position 9. Isolated from Chaetomium longirostre, it exhibits cytotoxic activities.
Eurysterol B
An organic sodium salt that is monosodium salt of eurysterol B sulfonic acid. Isolated from an undescribed marine sponge of the genus Euryspongia collected in Palau, it is cytotoxic and exhibits antifungal activity against both amphotericin B-resistant and wild-type strains of Candida albicans.
sodium(E)-((1R,4aS,4bS,8aS,10aS)-1-(2-((2S,5R)-2,5-dimethoxy-2,5-dihydrofuran-3-yl)ethyl)-4b,8,8,10a-tetramethyldecahydrophenanthren-2(1H,3H,4bH)-ylidene)methyl sulfate
A natural product found in Coscinoderma species.
1-(4-fluorophenyl)-3-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-(phenylmethyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]urea
(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[3-[(8S,9R,10S,13R,14R,17S)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoyloxy]oxane-2-carboxylic acid
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
Pyrophaeophorbide a
Pyropheophorbide-a (Ppa) is a promising photosensitizer for tumor photodynamic therapy (PDT)[1].
3-Hydroxy-beta-ionol 3-[glucosyl-(1->6)-glucoside]
(6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(1r,3s,4s,5r,7s,8r,9s,10z,12s,13s,14s)-4,8,9-tris(acetyloxy)-3,6,6,10,14-pentamethyl-2-oxo-16-oxatetracyclo[10.3.1.0¹,¹².0⁵,⁷]hexadec-10-en-13-yl acetate
(1e,3s,4s,6s,9r,11s,12s,14s)-3,9,12-tris(acetyloxy)-14-hydroxy-7,11,16,16-tetramethyl-10-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1,7-dien-6-yl acetate
4,8,9-tris(acetyloxy)-3,6,6,10,14-pentamethyl-2-oxo-16-oxatetracyclo[10.3.1.0¹,¹².0⁵,⁷]hexadec-10-en-13-yl acetate
3-amino-2-hydroxy-n-[(6s,7r)-7,10,10-trimethyl-12-(2-methylpropyl)-2,5,9,11-tetraoxo-3-(sec-butyl)-1,4,8-trioxacyclododecan-6-yl]benzenecarboximidic acid
(2e,4e,6e)-n-{5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl}-10-methylundeca-2,4,6-trienimidic acid
n-[7-(butanoyloxy)-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid
(3r,4r,5s,7s,10s,11r,13s)-7,10,13-tris(acetyloxy)-3-hydroxy-4,14,15,15-tetramethyl-2-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1(14),8-dien-5-yl acetate
(1r,2r,3r,4r,6s,8s,9r,10s,11s,13r)-2,3,8-tris(acetyloxy)-6-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
[2,10,13-tris(acetyloxy)-5-hydroxy-8,12,15,15-tetramethyl-9-oxobicyclo[9.3.1]pentadeca-3,7,11-trien-4-yl]methyl acetate
(4s)-4-[(3r)-3-{[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}butyl]-3,5,5-trimethylcyclohex-2-en-1-one
4-(3-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}butyl)-3,5,5-trimethylcyclohex-2-en-1-one
(4s)-4-hydroxy-3,5,5-trimethyl-4-[(3r)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one
2,5-dimethoxy-3-[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]-6-[1-(2-methylbut-3-en-2-yl)indol-3-yl]cyclohexa-2,5-diene-1,4-dione
(1s,2s,3r,5s,7r,8s,9s,10s,11r,15s)-3,10,15-tris(acetyloxy)-9-hydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-yl acetate
(1r,2r,3r,5s,7s,8s,9r,10r)-2,9,10-tris(acetyloxy)-5-hydroxy-8,12,15,15-tetramethyl-4-methylidene-13-oxotricyclo[9.3.1.0³,⁸]pentadec-11-en-7-yl acetate
6,7',11'-tris(acetyloxy)-3,3-dimethyl-10'-methylidene-2'-oxo-3'-oxaspiro[cyclohexane-1,5'-tricyclo[7.2.1.0¹,⁶]dodecan]-2-ylmethyl acetate
(6as)-3-[(1s,2s,4r)-4-hydroxy-2-methyl-6-oxocyclohexyl]-6a-methyl-9-[(2e)-4,6,8-trimethyldeca-2,4-dienoyl]furo[2,3-h]isochromene-6,8-dione
2α,5α,7β,13α-tetraacetoxy-10β-hydroxy-2(3→20)abeotaxan-9-one
{"Ingredient_id": "HBIN005246","Ingredient_name": "2\u03b1,5\u03b1,7\u03b2,13\u03b1-tetraacetoxy-10\u03b2-hydroxy-2(3\u219220)abeotaxan-9-one","Alias": "NA","Ingredient_formula": "C28H38O10","Ingredient_Smile": "CC1=C2C(C(=O)C3(CC(=CC(C(C2(C)C)CC1OC(=O)C)OC(=O)C)C(CC3OC(=O)C)OC(=O)C)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21013","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}